Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 478 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transdermal patch Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts

NCT04994444
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Nicoderm CQ 21Mg/24Hr Transdermal System
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Not applicable Interventional

Direct to Smoker Outreach in a Health Care Setting

NCT01321944
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Direct to Smoker Outreach Program
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Revere, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Not applicable Interventional Results available

Androgen Effects in HIV-infected Women

NCT00095212
View directory record Official record
Conditions
HIV Infection
Interventions
1 Transdermal Testosterone (Patch), 2 Placebo Patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 3 Interventional Results available

Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

NCT01151098
View directory record Official record
Conditions
Chronic Nonmalignant Pain
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
19
States / cities
Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

NCT00505687
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
31 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • St. Petersburg, Florida • Fort Wayne, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems

NCT01323140
View directory record Official record
Conditions
Hypogonadism
Interventions
testosterone matrix transdermal system
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Fort Meyers, Florida • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 1, 2013 · Synced Oct 22, 2026, 8:00 AM EDT
Not listed Not applicable Interventional

Enhancing ADHD Driving Performance With Stimulant Medication

NCT00572026
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 25 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 3 Interventional

Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

NCT00349791
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Interventions
Testosterone Transdermal System, Placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 22, 2026, 8:00 AM EDT
Terminated Not applicable Interventional Results available

Analysis of Aldehyde Biomarkers of Exposure and Host Response

NCT00482690
View directory record Official record
Conditions
Smoking Cessation
Interventions
nicotine polacrilex, nicotine transdermal system, nicotine inhaler
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 4 Interventional Results available

Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach

NCT04112368
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone 200mg, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 22, 2026, 8:00 AM EDT
Recruiting Phase 2 Interventional

Role of Estrogen on Skeletal Outcomes in FHA

NCT07010146
View directory record Official record
Conditions
Bone Strength, Bone Density, FHA (Functional Hypothalamic Amenorrhea)
Interventions
transdermal 17β-E2 with cyclic progestin, oral 17β-E2 with cyclic progestin, transdermal EE+LNG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
14 Years to 30 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants

NCT02608320
View directory record Official record
Conditions
Healthy
Interventions
Duragesic (Fentanyl Transdermal System [TDS] Small Patches), New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches), Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches), Duragesic (Fentanyl TDS Large Patches), New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches), Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 1 Interventional Results available

A Treatment Study for Premenstrual Syndrome (PMS)

NCT00001259
View directory record Official record
Conditions
Premenstrual Syndrome, Menstruation Disturbances
Interventions
Leuprolide, Estradiol Patches, Progesterone, Placebo patch, Placebo injection, Placebo suppository
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®

NCT00546650
View directory record Official record
Conditions
Healthy
Interventions
Sumatriptan succinate
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Not applicable Interventional

Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD

NCT01990079
View directory record Official record
Conditions
PTSD, Smoking
Interventions
Bupropion, nicotine replacement therapy, Smoking cessation counseling, mobile contingency management, Stay Quit Coach
Drug · Other · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 22, 2026, 8:00 AM EDT
Terminated Phase 4 Interventional Results available

Postpartum Depression: Transdermal Estradiol Versus Sertraline

NCT00744328
View directory record Official record
Conditions
Postpartum Depression
Interventions
Transdermal Estradiol, Sertraline, Placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT)

NCT00326781
View directory record Official record
Conditions
Smoking
Interventions
Nicoderm Transdermal Patch, Nicotine Nasal Spray
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
674 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

NCT01596400
View directory record Official record
Conditions
Chemotherapy Induced Nausea and Vomiting
Interventions
granisetron transdermal system, Granisetron IV
Drug
Lead sponsor
Kyowa Kirin Pharmaceutical Development Ltd
Industry
Eligibility
13 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 22, 2026, 8:00 AM EDT
Not listed Phase 2 Interventional

Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome

NCT01544283
View directory record Official record
Conditions
Shoulder Pain
Interventions
Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch, Triamcinolone Acetonide
Drug
Lead sponsor
Injury Care Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Combining Placing a Synera Patch With Propofol/Lidocaine Mixture to Decrease Pain With IV Propofol Injection

NCT02240628
View directory record Official record
Conditions
Pain on IV Injection of Propofol.
Interventions
Lidocaine/tetracaine transdermal patch, Saline, Lidocaine
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
6 Years to 17 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.

NCT04663464
View directory record Official record
Conditions
Healthy Volunteers
Interventions
abaloparatide-sMTS, abaloparatide-SC
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Phase 1 Interventional

Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)

NCT02192021
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma
Interventions
Micro needle array-Doxorubicin (MNA-D)
Drug
Lead sponsor
Falo, Louis, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 22, 2026, 8:00 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers

NCT01892813
View directory record Official record
Conditions
Nicotine Dependence, Tobacco Use
Interventions
Nicotine replacement therapy - Transdermal nicotine patch, Nicotine replacement therapy - Nicotine gum, Nicotine replacement therapy - Nicotine lozenge, Bupropion, Varenicline, Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum, Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge, Combination pharmacotherapy - Transdermal nicotine patch + bupropion, Tobacco quitline referral, Tailored behavioral intervention, Alcohol use risk reduction, Behavioral activation for depressive symptoms, Behavioral management of postcessation weight gain
Drug · Behavioral
Lead sponsor
Mark Vander Weg
Other
Eligibility
18 Years to 99 Years
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 22, 2026, 8:00 AM EDT
Completed Not applicable Interventional Results available

Lidocaine 5% Patch (Lidoderm) for the Prevention of Acute and Chest Pain Following Robotic Valve Surgery

NCT03120351
View directory record Official record
Conditions
Perioperative Chest Pain
Interventions
Lidoderm 5 % Topical Patch, Placebo patch
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 22, 2026, 8:00 AM EDT